Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, Sondak VK, Messina JL, Babacan NA, Maria-Engler SS, De Armas L, Williams SL, Gatenby RA, Chen YA, Anderson ARA, Smalley KSM.

EBioMedicine. 2019 Oct;48:178-190. doi: 10.1016/j.ebiom.2019.09.023. Epub 2019 Oct 5.

2.

Viruses in Skin Cancer (VIRUSCAN): Study design and baseline characteristics of a prospective clinic-based cohort study.

Amorrortu RP, Fenske NA, Cherpelis BS, Vijayan L, Zhao Y, Balliu J, Messina JL, Sondak VK, Giuliano AR, Gheit T, Tommasino M, Rollison DE.

Cancer Epidemiol Biomarkers Prev. 2019 Aug 19. pii: cebp.0446.2019. doi: 10.1158/1055-9965.EPI-19-0446. [Epub ahead of print]

PMID:
31427307
3.

Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins.

Weitman ES, Perez MC, Lee D, Kim Y, Fulp W, Sondak VK, Sarnaik AA, Gonzalez RJ, Cruse CW, Messina JL, Zager JS.

Melanoma Manag. 2019 Apr 26;6(2):MMT17. doi: 10.2217/mmt-2018-0011. eCollection 2019 Jun.

4.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.

Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS.

Clin Cancer Res. 2019 Oct 1;25(19):5961-5971. doi: 10.1158/1078-0432.CCR-18-4159. Epub 2019 Aug 9.

PMID:
31399473
5.

Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma.

Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J.

Pigment Cell Melanoma Res. 2019 Jul 22. doi: 10.1111/pcmr.12813. [Epub ahead of print]

PMID:
31329344
6.

Echoes of a failure: what lessons can we learn?

Sondak VK, Khushalani NI.

Lancet Oncol. 2019 Aug;20(8):1037-1039. doi: 10.1016/S1470-2045(19)30312-2. Epub 2019 Jun 17. No abstract available.

PMID:
31221617
7.

Current Immunotherapy Practices in Melanoma.

Rothermel LD, Sarnaik AA, Khushalani NI, Sondak VK.

Surg Oncol Clin N Am. 2019 Jul;28(3):403-418. doi: 10.1016/j.soc.2019.02.001. Epub 2019 Apr 12. Review.

PMID:
31079796
8.

Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival.

Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, White RL, Faries MB, Schneebaum S, Mozzillo N, Charney KJ, Sondak VK, Messina JL, Zager JS, Han D.

Ann Surg Oncol. 2019 Jul;26(7):2254-2262. doi: 10.1245/s10434-019-07369-w. Epub 2019 Apr 22.

PMID:
31011906
9.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM.

Cancer Res. 2019 Jun 1;79(11):2947-2961. doi: 10.1158/0008-5472.CAN-19-0040. Epub 2019 Apr 15.

PMID:
30987999
10.

Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit.

Klemen ND, Han G, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Charney K, Hoekstra H, Sondak VK, Messina JL, Zager JS, Han D.

J Surg Oncol. 2019 Jun;119(8):1053-1059. doi: 10.1002/jso.25444. Epub 2019 Mar 18.

PMID:
30883771
11.

Management of intussusception in patients with melanoma.

Perez MC, Sun J, Farley C, Han D, Sun AH, Narayan D, Lowe M, Delman KA, Messina JL, Gonzalez RJ, Sondak VK, Khushalani NI, Zager JS.

J Surg Oncol. 2019 Jun;119(7):897-902. doi: 10.1002/jso.25393. Epub 2019 Feb 7.

PMID:
30734297
12.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
13.

Microsatellitosis in Patients with Melanoma.

Karakousis GC, Gimotty PA, Leong SP, Pockaj BA, White RL, O'Donoghue C, Sinnamon AJ, Bartlett EK, Dueck AC, Gould Rothberg BE, Messina JL, Vetto JT, Sondak VK, Schneebaum S, Kashani-Sabet M, Han D, Faries MB, Zager JS; with the Sentinel Lymph Node Working Group.

Ann Surg Oncol. 2019 Jan;26(1):33-41. doi: 10.1245/s10434-018-7006-4. Epub 2018 Nov 12.

PMID:
30421045
14.

Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?

Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS.

Ann Surg Oncol. 2019 Feb;26(2):379-385. doi: 10.1245/s10434-018-6810-1. Epub 2018 Oct 11.

PMID:
30311164
15.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
16.

Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience.

Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB.

Melanoma Manag. 2018 Apr 9;5(1):MMT02. doi: 10.2217/mmt-2017-0025. eCollection 2018 Jun.

17.

Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?

Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS.

Ann Surg Oncol. 2018 Oct;25(11):3334-3340. doi: 10.1245/s10434-018-6688-y. Epub 2018 Aug 2.

PMID:
30073600
18.

Surgical management of melanoma.

Burke EE, Sondak VK.

Semin Cutan Med Surg. 2018 Jun;37(2):101-108. doi: 10.12788/j.sder.2018.018. Review.

PMID:
30040086
19.

Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience.

Prieto-Granada C, Castner N, Chen A, Li J, Yue B, Wong JY, Iyengar S, Sondak VK, Zager JS, Messina JL.

Pathol Oncol Res. 2018 Jun 14. doi: 10.1007/s12253-018-0427-3. [Epub ahead of print]

PMID:
29948620
20.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

21.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.

Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM.

Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19.

22.

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA.

Front Oncol. 2018 Mar 2;8:44. doi: 10.3389/fonc.2018.00044. eCollection 2018.

23.

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 May 15;124(10):2254-2255. doi: 10.1002/cncr.31261. Epub 2018 Mar 15. No abstract available.

24.

Stratifying SLN incidence in intermediate thickness melanoma patients.

Chang JM, Kosiorek HE, Dueck AC, Leong SPL, Vetto JT, White RL, Avisar E, Sondak VK, Messina JL, Zager JS, Garberoglio C, Kashani-Sabet M, Pockaj BA.

Am J Surg. 2018 Apr;215(4):699-706. doi: 10.1016/j.amjsurg.2017.12.009. Epub 2017 Dec 14.

25.

Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials.

Sreeraman Kumar R, Thapa R, Kim Y, Khushalani NI, Sondak VK, Reed DR.

Cancer Med. 2018 Apr;7(4):991-996. doi: 10.1002/cam4.1307. Epub 2018 Feb 25.

26.

Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus.

Porubsky C, Teer JK, Zhang Y, Deschaine M, Sondak VK, Messina JL.

J Cutan Pathol. 2018 Feb;45(2):180-183. doi: 10.1111/cup.13082. Epub 2017 Dec 17.

27.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM.

Mol Cancer Ther. 2018 Jan;17(1):73-83. doi: 10.1158/1535-7163.MCT-17-0196. Epub 2017 Nov 13.

28.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

29.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

30.

High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.

31.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

32.

Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy-This Time It's Personal.

Sondak VK, Messina JL, Zager JS.

JAMA Dermatol. 2017 Sep 1;153(9):857-858. doi: 10.1001/jamadermatol.2017.2496. No abstract available.

PMID:
28724141
33.

BRAF-MEK inhibition in melanoma brain metastases: a new hope.

Forsyth PA, Smalley KSM, Sondak VK.

Lancet Oncol. 2017 Jul;18(7):836-837. doi: 10.1016/S1470-2045(17)30449-7. No abstract available.

PMID:
28677560
34.

Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma.

Sondak VK, Khushalani NI.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):16-17. doi: 10.1016/j.ijrobp.2017.02.224. No abstract available.

PMID:
28586957
35.

Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB.

J Natl Compr Canc Netw. 2017 Apr;15(4):473-482.

PMID:
28404758
36.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
37.

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes.

Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS.

Am Surg. 2016 Nov 1;82(11):1109-1116.

PMID:
28206940
38.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

39.

Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions.

Glazer ES, Porubsky CF, Francis JD, Ibanez J, Castner N, Messina JL, Sarnaik AA, Harrington MA, Cruse CW, Sondak VK, Zager JS.

Ann Plast Surg. 2017 Jun;78(6):663-667. doi: 10.1097/SAP.0000000000000949.

40.

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

Sharma R, Fedorenko I, Spence PT, Sondak VK, Smalley KS, Koomen JM.

J Proteome Res. 2016 Dec 2;15(12):4476-4489. Epub 2016 Nov 17.

41.

Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin.

Hampras SS, Reed RA, Bezalel S, Cameron M, Cherpelis B, Fenske N, Sondak VK, Messina J, Tommasino M, Gheit T, Rollison DE.

J Skin Cancer. 2016;2016:1368103. Epub 2016 Nov 7.

42.

Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun.

Gershenwald JE, Halpern AC, Sondak VK.

JAMA. 2016 Nov 8;316(18):1913-1914. doi: 10.1001/jama.2016.16430. No abstract available.

PMID:
27824997
43.

Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma.

Sarnaik AA, Zager JS, Sondak VK.

Oncology (Williston Park). 2016 Oct 15;30(10):891-2, 895. No abstract available.

44.

Resistance patterns to anti-PD-1 therapy in metastatic melanoma.

Ozgun A, Sondak VK, Markowitz J.

Chin Clin Oncol. 2016 Dec;5(6):75. doi: 10.21037/cco.2016.08.01. Epub 2016 Aug 22. No abstract available.

45.

Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies.

Doepker MP, Yamamoto M, Applebaum MA, Patel NU, Jaime Montilla-Soler M, Sarnaik AA, Wayne Cruse C, Sondak VK, Zager JS.

Ann Surg Oncol. 2017 Feb;24(2):355-361. doi: 10.1245/s10434-016-5590-8. Epub 2016 Sep 22.

46.

A Comprehensive Approach to Pediatric Atypical Melanocytic Neoplasms with Comment on the Role of Sentinel Lymph Node Biopsy.

Sondak VK, Reed D, Messina JL.

Crit Rev Oncog. 2016;21(1-2):25-36. doi: 10.1615/CritRevOncog.2016016109. Review.

PMID:
27481000
47.

Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma.

Khushalani NI, Sondak VK.

Lancet Oncol. 2016 Sep;17(9):1178-9. doi: 10.1016/S1470-2045(16)30368-0. Epub 2016 Jul 30. No abstract available.

PMID:
27480104
48.

Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck.

Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB.

Head Neck. 2017 Jan;39(1):48-55. doi: 10.1002/hed.24527. Epub 2016 Jun 14.

PMID:
27300153
49.

Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma.

Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ.

Ann Surg Oncol. 2016 Oct;23(11):3572-3578. doi: 10.1245/s10434-016-5293-1. Epub 2016 Jun 1.

PMID:
27251134
50.

Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.

Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P.

J Natl Cancer Inst. 2016 May 31;108(9). pii: djw042. doi: 10.1093/jnci/djw042. Print 2016 Sep.

Supplemental Content

Loading ...
Support Center